Florida vs Georgia Cannabis Laws

Florida is the largest medical-only cannabis market in the United States and one of the most important markets for publicly traded cannabis companies. Amendment 2 legalized medical cannabis in 2016 with 71% voter approval, and the state's medical program has grown to serve over 850,000 active patients — the largest patient registry in the nation. Annual medical cannabis sales exceed $2.5 billion.

The Florida market operates under a vertically integrated license model known as MMTC (Medical Marijuana Treatment Center) licenses. Each licensee must cultivate, process, and dispense its own cannabis products, creating high barriers to entry but also protecting established operators from new competition. The state has issued a limited number of licenses, making each one extremely valuable. A 2024 ballot measure to legalize recreational cannabis received 57% voter support but fell short of Florida's 60% supermajority threshold.

Florida is a critical market for nearly every major MSO. Trulieve, which is headquartered in the state, operates the largest dispensary network with over 130 locations. Curaleaf, Green Thumb Industries, Cresco Labs, Verano, TerrAscend, and Ayr Wellness also maintain significant Florida operations. The state's large population of 22 million, strong tourism industry, and affluent retiree demographic make it one of the most commercially attractive cannabis markets regardless of its medical-only status.

Georgia's cannabis landscape is extremely limited. The Haleigh's Hope Act, signed in 2015, created a medical cannabis registry allowing qualifying patients to possess low-THC oil containing no more than 5% THC. However, the law did not initially authorize in-state production or sales, creating a paradox where patients could legally possess the oil but had no legal means to obtain it within the state.

HB 324, signed in 2019, attempted to address this by establishing the Georgia Access to Medical Cannabis Commission (GAMCC) and authorizing up to 6 production licenses for in-state manufacturing and distribution of low-THC oil. The licensing process was marred by legal challenges and delays, and the first products did not reach patients until 2023. The program remains nascent, with only a handful of dispensary locations operational.

Georgia's cannabis market is among the most restrictive in the nation. Only low-THC oil products are permitted — smokable flower, edibles, concentrates, and other standard cannabis products are illegal. Qualifying conditions include cancer, seizure disorders, Crohn's disease, ALS, Parkinson's disease, and several other specified illnesses. The extremely limited product scope and small number of licenses severely constrain the market's potential, and no major MSOs have entered the state. Annual sales are estimated at roughly $25 million, making Georgia one of the smallest legal cannabis markets in the country.